Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia.
Vaccine Immunology, Murdoch Children's Research Institute, Parkville, VIC, Australia.
J Med Virol. 2024 Jun;96(6):e29732. doi: 10.1002/jmv.29732.
Neutralizing antibodies (NAbs) are considered the primary mechanism of vaccine-mediated protection against human papillomaviruses (HPV), the causative agent of cervical cancer. However, the minimum level of NAb needed for protection is currently unknown. The HPV pseudovirion-based neutralization assay (PBNA) is the gold standard method for assessing HPV antibody responses but is time-consuming and labor-intensive. With the development of higher valency HPV vaccines, alternative serological assays with the capacity for multiplexing would improve efficiency and output. Here we describe a multiplex bead-based immunoassay to characterize the antibody responses to the seven oncogenic HPV types (HPV16/18/31/33/45/52/58) contained in the current licensed nonavalent HPV vaccine. This assay can measure antibody isotypes and subclasses (total IgG, IgM, IgA1-2, IgG1-4), and can be adapted to measure other antibody features (e.g., Fc receptors) that contribute to vaccine immunity. When tested with serum samples from unvaccinated and vaccinated individuals, we found high concordance between HPV-specific IgG using this multiplex assay and NAbs measured with PBNA. Overall, this assay is high-throughput, sample-sparing, and time-saving, providing an alternative to existing assays for the measurement and characterization of HPV antibody responses.
中和抗体（NAb）被认为是疫苗介导的针对人乳头瘤病毒（HPV）保护的主要机制，HPV 是宫颈癌的致病因子。然而，目前尚不清楚预防所需的 NAb 最低水平。HPV 假病毒中和测定（PBNA）是评估 HPV 抗体反应的金标准方法，但耗时耗力。随着高价 HPV 疫苗的发展，具有多重检测能力的替代血清学检测方法将提高效率和产出。在这里，我们描述了一种用于表征当前批准的九价 HPV 疫苗中包含的七种致癌 HPV 类型（HPV16/18/31/33/45/52/58）抗体反应的多重基于珠的免疫测定法。该测定法可以测量抗体同种型和亚类（总 IgG、IgM、IgA1-2、IgG1-4），并且可以适应于测量有助于疫苗免疫的其他抗体特征（例如 Fc 受体）。用未接种和接种疫苗的个体的血清样本进行测试时，我们发现该多重测定法测量的 HPV 特异性 IgG 与 PBNA 测量的 NAb 之间高度一致。总的来说，该测定法具有高通量、节省样本和节省时间的特点，为 HPV 抗体反应的测量和表征提供了一种替代现有检测方法的方法。
